Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion

Neuroscience

Volumn 170, Issue 3, 2010, Pages 846-857

  Gamboa, J ^a   Blankenship, D A ^b   Niemi, J P ^b   Landreth, G E ^b   Karl, M ^b   Hilow, E ^b   Sundararajan, S ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral ischemia; Neuroprotection; Pioglitazone; PPAR ; Rosiglitazone

Indexed keywords

GLITAZONE DERIVATIVE; INTERCELLULAR ADHESION MOLECULE 1; MYELOPEROXIDASE; PIOGLITAZONE; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENCEPHALITIS; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY;

ANIMALS; BEHAVIOR, ANIMAL; BLOOD PRESSURE; BRAIN; BRAIN ISCHEMIA; CELL ADHESION MOLECULES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; INFARCTION, MIDDLE CEREBRAL ARTERY; LEUKOCYTES; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; REGIONAL BLOOD FLOW; REPERFUSION; STROKE; THIAZOLIDINEDIONES;

EID: 77956504399     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.07.063     Document Type: Article

References (42)

1. Allahtavokoli M., Shabanzadeh A., Sadr S., Parviz M., Djahanguiri B. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. Clin Exp Pharmacol Physiol 2006, 33:1052-1058.
2. Barman Balfour J., Plosker G. Rosiglitazone. Drugs 1999, 57:921-930.
3. Calnek D., Mazzella L., Roser S., Roman J., Hart M. Peroxisome proliferator-activated receptor g ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003, 23:52-57.
4. Chen J., Sanberg P., Li Y., Wang L., Lu M., Willing A., Sanchez-Ramos J., Chopp M. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001, 32:2682-2688.
5. Cho D.H., Choi Y., Jo S., Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment troglitazone. J Biol Chem 2004, 279:2499-2506.
6. Clark R., Lee E., White R., Jonak Z., Feuerstein G., Barone F. Reperfusion following focal stroke hastens inflammation and resolution of ischemic injured tissue. Brain Res Bull 1994, 35:387-392.
7. Culman J., Zhao Y., Gohlke P., Herdegen T. PPAR-gamma: therapuetic target for ischemic stroke. Trends Pharmacol Sci 2007, 28:244-249.
8. Cuzzocrea S., Pisano B., Dugo L., Ianoro A., Patel N., Di Paola R., Genovese T., Chatterjee P., Di Rosa M., Caputi A., Thiemermann C. Rosiglitazone and 15-deoxy-D12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-g (PPAR-g), reduce ischemia/reperfusion injury of the gut. Br J Pharmacol 2003, 140:366-376.
9. Diab A., Deng C., Smith J., Hussain R., Phanavanh B., Lovett-Racke A., Drew P., Racke M. Peroxisome proliferator-activated receptor-g agonist 15-deoxy-D12,14-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168:2508-2515.
10. Festuccia W., Oztezcan S., Laplante M., Berthiaume M., Michel C., Dohgu S., Denis R., Brito M., Brito N., Miller D., Banks W., Bartness T., Richard D., Deshaies Y. Peroxisome proliferator-activated receptor-g-mediated positive energy balance in the rat is associated with reduced symptahtetic drive to adipose tissues and thyroid status. Endocrinologist 2008, 149:2121-2130.
11. Fisher M., Feuerstein G., Howells D., Hurn P., Kent T., Savitz S., Lo E. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250.
12. Frijns C., Kappelle L. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 2002, 33:2115-2122.
13. Garcia J., Liu K., Yoshida Y., Lian J., Chen S., del Zoppo G. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol 1994, 144:188-199.
14. Hwang J., Kleinhenz D., Lassegue B., Griendling K., Dikalov S., Hart C.M. Peroxisome proliferator-activated-g ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2007, 288:C899-C905.
15. Kapadia R., Yi J., Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008, 13:1813-1826.
16. Kawamura S., Li Y., Shirasawa M., Nobuyuki Y., Fukasawa H. Reversible middle cerebral artery occlusion in rats using an intraluminal thread technique. Surg Neurol 1994, 41:368-373.
17. Kinouchi H., Epstein C., Mizui T., Carlson E., Chen S., Chan P. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc Natl Acad Sci U S A 1991, 88:11158-11162.
18. Lin T.N., Cheung W.M., Wu J.S., Lin H., Chen J.J., Liou J.Y., Shyue S.K., Wu K. 15D-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 2006, 26:481-487.
19. Longa E., Weinstein P., Carlson S. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20:84-91.
20. Luo Y., Yin W., Signore A., Zhang F., Hong Z., Wang S., Graham S., Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006, 97:435-448.
21. Maier C., Hsieh L., Crandall T., Narasimhan P., Chan P. A new approach for the investigation of reperfusion-related brain injury. Biochem Soc Trans 2006, 34:1366-1369.
22. Pereira M., Hurtado O., Cardenas A., Bosca L., Castillo J., Davalos A., Vivancos J., Serena J., Lorenzo P., Lizasoain I., Moro M. Rosiglitazone and 15D-deoxy-delta 12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 2006, 26:218-229.
23. Saver J., Kidwell C., Eckstein M., Starkman S. Prehospital neuroprotective therapy for acute stroke results of the field administration for stroke therapy-magnesium (FAST-MAG) pilot trial. Stroke 2004, 35:e106-e108.
24. Schaller B., Graf R. Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab 2004, 24:351-371.
25. Schallert T., Fleming S., Leasure J., Tillerson J., Bland S. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
26. Seimandi M., Lemaire G., Pillon A., Perrin A., Carlavan I., Voegel J., Vignon F., Nicolas J., Balaguer P. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem 2005, 344:8-15.
27. Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H., Greenberg J. A peroxisome proliferator-activated receptor-g agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005, 36:353-359.
28. Straus D., Glass C. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007, 28:551-558.
29. Recommendations for standards regarding pre-clinical neuroprotective and restorative drug development. Stroke 1999, 30:2752-2758. Stroke Therapy Academic Industry Roundtable.
30. Sundararajan S., Gamboa J., Victor N., Wanderi E., Lust W., Landreth G. PPARg ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005, 130:685-696.
31. Tang W., Maroo A. PPARg agonists: safety issues in heart failure. Diabetes Obes Metab 2009, 9:447-454.
32. Tureyen K., Kapadia R., Bowen K., Satriotomo I., Jiang J., Feinstein D., Vemuganti R. Peroxisome proliferator-activated receptor-g agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007, 101:41-56.
33. Victor N., Wanderi E., Gamboa J., Zhao X., Aronowski J., Lust W., Landreth G., Sundararajan S. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 2006, 24:1653-1663.
34. Waugh J., Keating G., Plosker G., Easthope S., Robinson D. Pioglitazone, a review of its use in type 2 diabetes mellitus. Drugs 2007, 66:85-109.
35. Wayman N., Hattori Y., McDonald M., Mota-Filipe H., Cuzzocrea S., Pisano B., Chatterjee P., Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-g and PPAR-a) reduce myocardial infarct size. FASEB J 2002, 16:1027-1040.
36. Welch J., Ricote M., Akiyama T., Gonzalez F., Glass C. PPARg and PPARd negatively regulate specific subsets of lipopolysaccharide and IFN-g target genes in macrophages. Proc Natl Acad Sci U S A 2003, 100:6712-6717.
37. Yonemori F., Yamaguchi T., Yamada H., Tamura A. Evaluation of motor deficit after chronic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1998, 18:1099-1106.
38. Young P., Buckle D., Cantello B., Chapman H., Clapham J., Coyle P., Haigh D., Hindley R., Holder J., Kallender H., Latter A., Lawrie K., Mossakowska D., Murphy G., Roxbee Cox L., Smith S. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 2007, 284:751-759.
39. Zhang R., Chopp M., Li Y., Zaloga C., Jiang N., Jones M., Miyasaka M., Ward P. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurologist 1994, 44:1747-1751.
40. Zhao X., Sun G., Zhang J., Strong R., Song W., Gonzales N., Grotta J., Aronowski J. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol 2007, 61:352-362.
41. Zhao X., Zhang Y., Strong R., Grotta J., Aronowski J. 15d-prostaglandin J(2) activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2006, 26:811-820.
42. Zhao Y., Patzer A., Gohlke P., Herdegen T., Culman J. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci 2005, 22:278-282.